Ya‐Hui Wang, Ya‐Hui Chuang, Chih‐Feng Wu, Meng‐Chin Jan, Wan‐Jung Wu, Chih‐Lin Lin, Chun‐Jen Liu, Ya‐Chien Yang, Pei‐Jer Chen, Shi‐Ming Lin, Mong‐Hsun Tsai, Yi‐Wen Huang, Ming‐Whei Yu – 1 November 2018 – Smoking interacts with hepatitis B virus (HBV) to increase the risk of hepatocellular carcinoma (HCC), which might be explained by its role in antiviral immunity. We evaluated the potential mediating role of viral load and/or alanine aminotransferase (ALT) in the relation of smoking with HBV‐associated HCC risk.

Elliot B. Tapper, Jad Baki, Neehar D. Parikh, Anna S. Lok – 1 November 2018 – Cirrhosis is associated with disabling symptoms and diminished health‐related quality of life (HRQOL). However, for patients with compensated disease, data are limited regarding associations with poor patient‐reported outcomes (PROs). We prospectively enrolled 300 patients with cirrhosis and portal hypertension without a history of hepatic encephalopathy (HE) and reviewed medical and pharmacy records.

Michael J. Flynn, Anwar A. Sayed, Rohini Sharma, Abdul Siddique, David J. Pinato – 1 November 2018 – After a decade of stagnation in drug development, therapeutic reversal of immune‐exhaustion with immune checkpoint inhibitors (ICPIs) has been shown to be effective in advanced hepatocellular carcinoma (HCC). The clinical development of novel ICPIs continues at a rapid pace, with more than 50 clinical trials of immunotherapeutic agents registered as of May 2018 for this indication.

1 November 2018

Giuseppe Indolfi, Silvia Ricci – 1 November 2018

Michael J. Flynn, Anwar A. Sayed, Rohini Sharma, Abdul Siddique, David J. Pinato – 1 November 2018 – After a decade of stagnation in drug development, therapeutic reversal of immune‐exhaustion with immune checkpoint inhibitors (ICPIs) has been shown to be effective in advanced hepatocellular carcinoma (HCC). The clinical development of novel ICPIs continues at a rapid pace, with more than 50 clinical trials of immunotherapeutic agents registered as of May 2018 for this indication.

Ismail Labgaa, Nicolas Demartines, Emmanuel Melloul – 1 November 2018

Christopher J. Danford, Margery A. Connelly, Irina Shalaurova, Misung Kim, Mark A. Herman, Imad Nasser, James D. Otvos, Nezam H. Afdhal, Z. Gordon Jiang, Michelle Lai – 1 November 2018 – Nonalcoholic fatty liver disease (NAFLD) is a complex disease dictated by both genetic and environmental factors. While insulin resistance (IR) is a key pathogenic driver, two common genetic variants in patatin‐like phospholipase domain containing 3 (PNPLA3) and transmembrane 6 superfamily member 2 (TM6SF2) also impart significant risk for disease progression.

The overall objective of this activity is to address the epidemiology, risk factors and key challenges in the evaluation and management of cardiovascular disease risk factors in liver transplant recipients. In particular, we will discuss practical approaches and pharmacologic considerations in the prevention and management of hypertension, dyslipidemia and diabetes in liver transplant recipients.  We will utilize a live webinar format that will be recorded for on demand viewing on Liver Learning ® .Manhal Izzy (Moderator) Dr.

Manuela Cesaretti, Pietro Addeo, Luigi Schiavo, Rodolphe Anty, Antonio Iannelli – 31 October 2018 – The growing number of patients on waiting lists for liver transplantation and the shortage of organs have forced many centers to adopt extended criteria for graft selection, moving the limit of acceptance for marginal livers. Steatotic grafts that were, in the past, considered strictly unacceptable for transplantation because of the high risk of early nonfunction are now considered as a potential resource for organ implementation.